On Friday, the fledgling field of psychedelic medicine suffered a major setback. The FDA declined to approve MDMA-assisted therapy for PTSD, instead asking the drugmaker Lykos Therapeutics to conduct ...
Quality evidence is needed to support a new Medicare Part D medication therapy management (MTM) program performance measure, prompting a scoping review on MTM services and associated outcomes.
There is new evidence suggesting therapy may lead to higher recovery rates than medication in people over 60 who experience anxiety disorders, says Associate Professor Carly Johnco. Anxiety disorders ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results